N-methyl-2-(1-propylcyclopropyl)ethanamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-methyl-2-(1-propylcyclopropyl)ethanamine
• 化学式: C₉H₁₉N
• 分子量: 141.25
• InChiKey: OBYINDUHWATQFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Wu Frank

  公开号：US20140161801A1

  公开（公告）日：2014-06-12

  The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R 1 , R 2 , R 3 , R 3′ , R 4 , R 5 , R 6 , X, L, T, Z and q are as defined in the specification. The invention also relates to a process for preparing the same, a pharmaceutical composition and a pharmaceutical formulation containing the derivative, use of the derivative for treating excessive proliferative diseases and chronic obstructive pulmonary disease and use of the derivative in the manufacture of a medicament for treating excessive proliferative diseases and chronic obstructive pulmonary disease.

  该发明涉及一种喹唑啉衍生物，其通式表示为(I)，作为酪氨酸激酶抑制剂的药用可接受盐和立体异构体，其中R1、R2、R3、R3'、R4、R5、R6、X、L、T、Z和q如规范中所定义。该发明还涉及一种制备该衍生物的方法，包含该衍生物的药用组合物和药用配方，以及将该衍生物用于治疗过度增殖性疾病和慢性阻塞性肺病，以及将该衍生物用于制造用于治疗过度增殖性疾病和慢性阻塞性肺病的药物。
• AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE
  申请人：Hinova Pharmaceuticals Inc.

  公开号：EP3971176A1

  公开（公告）日：2022-03-23

  An aromatic amine androgen receptor (AR) and BET targeting protein degradation chimera compound and its use. Specifically provided is a compound represented by formula I. Experimental results show that the compound can target and degrade both AR and BRD4, and down-regulate the expression of AR and BRD4 proteins; the compound can inhibit the proliferation of a variety of prostate cancer cells; the compound can inhibit the proliferation of a prostate cancer cell line LNCaP/AR, which overexpresses the AR, and can achieve a good inhibition effect on a prostate cancer cell line 22RV1, which is resistant to a marketed prostate cancer drug (enzalutamide); the compound also shows good metabolic stability, and has a good application prospect in the preparation of an AR and/or BET protein degradation targeting chimera, and a drug for the treatment of related diseases regulated by the AR and BET.

  一种芳香胺雄激素受体（AR）和BET靶向蛋白降解嵌合物化合物及其用途。具体提供的是由式I表示的化合物。实验结果表明，该化合物可以靶向降解AR和BRD4，并下调AR和BRD4蛋白的表达；该化合物可以抑制多种前列腺癌细胞的增殖；该化合物可以抑制过表达AR的前列腺癌细胞系LNCaP/AR的增殖，并且对一种对市售前列腺癌药物（恩扎鲁胺）具有耐药性的前列腺癌细胞系22RV1具有良好的抑制效果；该化合物还表现出良好的代谢稳定性，在制备AR和/或BET蛋白降解靶向嵌合物和治疗由AR和BET调控的相关疾病的药物方面具有良好的应用前景。
• GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF
  申请人：CIOFFI Christopher L.

  公开号：US20110312931A1

  公开（公告）日：2011-12-22

  The compounds of the present invention are represented by the following formula (I): wherein the substituents R 1 , R 2 , R 3 , R 4 , (R 5 ) m , R 6 , A, X, and Y are as defined herein. The compounds are useful in methods of treating a disorder which is created by or is dependent upon inhibiting GlyT-1.

  本发明的化合物由以下公式（I）表示：其中，取代基R1、R2、R3、R4、（R5）m、R6、A、X和Y的定义如本文所述。这些化合物可用于治疗由抑制GlyT-1引起或依赖于GlyT-1抑制的疾病的方法。
• INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS
  申请人：Gilead Sciences, Inc.

  公开号：EP3492464A1

  公开（公告）日：2019-06-05

  Intermediates, used for preparing inhibitors of the hepatitis C virus, of the following formulae are disclosed

  公开了用于制备丙型肝炎病毒抑制剂的下列配方的中间体